Retatrutide is a once-weekly injectable peptide that functions as a “triple-agonist” (GIP, GLP-1, and GCG receptors) designed by Eli Lilly for treating obesity and type 2 diabetes. Phase 2 trials showed, on average, over 24% weight loss in 48 weeks at the highest dose, marking it as a highly potent potential therapy.
Key Details About Retatrutide:
- Mechanism: Unlike GLP-1s (e.g., Wegovy) or GIP/GLP-1s (e.g., Zepbound), retatrutide mimics three hormone receptors: GIP, GLP-1, and GCG (glucagon). This triple action increases metabolic activity and reduces appetite simultaneously.
- Weight Loss Efficacy: In studies, participants taking the 12mg dose achieved an average of 24.2% body weight reduction after 48 weeks, with 26% of this group losing at least 30% of their body weight.
- Trial Status: Currently in Phase 3 trials, with FDA approval potentially arriving by late 2026 or 2027.
